Prohost Biotech - Exclusive Biotech Research - A Comprehensive Resource for Biotech News

Travere Therapeutics: Treating IgA Nephropathy and Focal Segmental Glomerulosclerosis

October 14, 2022 0

IgA Nephropathy Searching for companies focused on treating severe diseases that have yet to find approved …

Treating Untreatable Disease – NASH

October 13, 2022 0

Prohost Letter #452 Treating Untreatable Disease - NASH Non Alcoholic Steatohepatitis The efforts spent on treating …

Amylyx Pharmaceuticals Announces FDA Approval of RELYVRIO™ for of ALS Leading to a Weird Stock Market Reception

September 30, 2022 0

Amylyx Pharmaceuticals in the NEWS Amylyx Pharmaceuticals (AMLX) announced that the U.S. FDA has approved RELYVRIO™ …

From Biogen and Eisai: Lecanemab Confirmatory Phase 3 Clarity Met Primary Endpoint for Early Alzheimer’s Disease

September 28, 2022 0

Biogen & Eisai Co and Early Alzheimer's Disease From Tokyo and Cambridge, Eisai Co., Ltd. and …

From bluebird bio: FDA Accelerated Approval for SKYSONA® Gene Therapy for Early, Active Cerebral Adrenoleukodystrophy

September 19, 2022 0

FDA Approves bluebird bio Product Skysona for Early, Active CALD SKYSONA is the first FDA approved …

Intellia Therapeutics: Excellent News from NTLA-2001 Phase 1 Clinical Trial

September 16, 2022 0

Intellia Therapeutics Intellia Therapeutics.(NTLA) and Regeneron Pharmaceuticals (REGN) today announced positive interim results from an ongoing Phase 1 …

Rhythm Pharmaceuticals & Akero Therapeutics: On the Morning of September 15, 2022

September 15, 2022 0

Rhythm Pharmaceuticals Rhythm Pharmaceuticals (RYTM): After soaring, based on great scientific and drug performance in treating …

Akero Therapeutics: Efruxifermin Met Primary Endpoint for Both Dose Groups in NASH Patients

September 13, 2022 0

Akero Therapeutics Akero Therapeutics (AKRO) - a clinical-stage company, today released topline data from HARMONY, a …

Amylyx Pharmaceuticals Announces FDA Advisory Committee Supports Approval of AMX0035 for ALS

September 8, 2022 0

Amylyx Pharmaceuticals in the News Amylyx Pharmaceuticals (AMLX): The U.S. FDA Peripheral and Central Nervous System Drugs Advisory Committee has …

IVERIC Bio: Undeniable Promising News Today

September 6, 2022 0

IVERIC Bio ~ September 6, 2022 IVERIC bio (ISEE) announced positive results from GATHER2 second Phase …

TG Therapeutics: Promising Investigational Monoclonal Antibody Ublituximab for Relapsing Form of M.S.

August 31, 2022 0

TG Therapeutics Results Published in NEJM TG Therapeutics (TGTX) results from the ULTIMATE I & II …

Intellia Therapeutics to Present Data from Clinical Trial of NTLA-2002 Aimed at Treating Hereditary Angioedema

August 30, 2022 0

Intellia Therapeutics to Present Interim Clinical Data from NTLA-2002 Trial for Hereditary Angioedema An abstract featuring interim …

Fate Therapeutics: Improving on Cellular Therapies

August 25, 2022 0

Fate Therapeutics: Developing Next Generation Cellular Therapies Fate Therapeutics (FATE) is a clinical-stage biopharmaceutical company developing first-in-class …

Important Data Will Be Presented by Regenxbio on August 30th

August 23, 2022 0

Regenxbio to Present Important Data Regenxbio (RGNX) will present important material at the Society for the …

Gilead Sciences Stock Rallies Following Improving Survival of Pre-Treated HR+/HER2- Metastatic Breast Cancer

August 15, 2022 0

Gilead Sciences Good News for Breast Cancer Gilead Sciences' (GILD) product Trodelvy® has significantly improved the Overall …

The FDA Advisory Committee Will Soon Review the NDA of Amylyx Pharmaceuticals’ Product AMX0035 for ALS

August 11, 2022 0

On September 7th the FDA Will Review Amylyx Pharmaceuticals NDA for ALS Treatment Amylyx Pharmaceuticals (AMLX) …

Hutchmed: Treating Advanced Metastatic Colorectal Cancer and Other Treatment Resistant Cancers

August 10, 2022 0

Hutchmed: Treating Advanced Refractory Metastatic Colorectal Cancer On August 8, 2022, Hutchmed (HCM) announced that pivotal global …

Reata Pharmaceuticals Announces Extension of Review Period for Omaveloxolone NDA for Friedreich’s Ataxia

August 9, 2022 0

Reata Pharmaceuticals in the NEWS Reata Pharmaceuticals (RETA) on August 8, 2022, after the U.S. financial …

Gilead Sciences: A Promising Acquisition. See Also: Genmab and BioNTech: A Promising Expansion

August 5, 2022 0

Gilead Sciences to Acquire MiroBio At $405 Million Gilead Sciences (GILD) and MiroBio - a privately …

Regenxbio to File a BLA Using the Accelerated Approval Pathway for RGX-121 for the Hunter Syndrome

August 3, 2022 0

Regenxbio in the NEWS Regenxbio (RGNX) announced, on August 3, 2022, its intention to file a …

Exclusive Market Insight

& Scientific analysis

Latest Articlesddd